TickerBrief

NVAX · Novavax, Inc.

Novavax Inc NVAX

Develops and sells protein-based vaccines, including a COVID-19 vaccine.

Industry
Biotechnology
Listed on
Nasdaq NMS
IPO
1973-05-16
Website
novavax.com

Daily brief

Novavax retreats as plague-outbreak fears recede

-9.87% to $11.32 from $12.56

What moved NVAX

  • Novavax shares fell after World Health Organization officials characterized the risk of a wider plague outbreak as low, a day after the stock had jumped roughly 20% on outbreak speculation.
  • The move followed reports of a plague-related death at a Russian laboratory that had stoked speculation about potential new vaccine demand.
  • Novavax remained up nearly 20% over the trailing three months despite the pullback.

Sources: 24/7 Wall St. · Yahoo Finance

Daily brief

Novavax rises after raising 2026 revenue outlook

+0.52% to $7.74 from $7.70

What moved NVAX

  • Second-quarter revenue of $57 million beat estimates by about $3.7 million, with a net loss of $0.32 per share narrower than the $0.38 loss expected.
  • Novavax raised its full-year 2026 revenue guidance to $235 million-$275 million from a prior $230 million-$270 million range.
  • Product sales rose about 76% to $19 million, driven by stronger demand for its Matrix-M adjuvant and higher sales to licensing partners.

Sources: MarketScreener · BioSpace

More on Novavax, Inc.

Financial history →

Debt and maturities →

Earnings

← All stocks

This content is for informational purposes only and is not investment advice. Always do your own research before making financial decisions.